Mostrar el registro sencillo del ítem

dc.contributor.authorAtallah, Edmond
dc.contributor.authorFreixo, Cristiana
dc.contributor.authorAlvarez-Alvarez, Ismael
dc.contributor.authorCubero, Francisco Javier
dc.contributor.authorGerbes, Alexander L
dc.contributor.authorKullak-Ublick, Gerd A
dc.contributor.authorAithal, Guruprasad P
dc.contributor.authorAithal
dc.date.accessioned2021-12-21T13:09:47Z
dc.date.available2021-12-21T13:09:47Z
dc.date.created2021-12-21
dc.date.issued2021-11-15
dc.identifier.citationEdmond Atallah, Cristiana Freixo, Ismael Alvarez-Alvarez, F.J Cubero, Alexander L. Gerbes, Gerd A. Kullak-Ublick & Guruprasad P. Aithal (2021) Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review, Expert Opinion on Drug Metabolism & Toxicology, 17:11, 1327-1343, DOI: 10.1080/17425255.2021.1999410es_ES
dc.identifier.urihttps://hdl.handle.net/10630/23505
dc.description.abstractIntroduction: Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical outcomes. Areas covered: This systematic review summarizes the available evidence for all biomarkers proposed to have a role in the diagnosis or prognosis of DILI. Following a comprehensive search, we included all types of studies in humans. We included DILI cases based on any threshold criteria but excluded intrinsic DILI, commonly caused by paracetamol overdose. We classified studies into diagnostic and prognostic categories and assessed their methodological quality. After reviewing the literature, 14 studies were eligible. Expert Opinion: Diagnostic studies were heterogeneous with regard to the study population and outcomes measured. Prognostic models were developed by integrating novel biomarkers, risk scores, and traditional biomarkers, which increased their prognostic ability to predict death or transplantation by 6 months. This systematic review highlights the case of need for non-genetic biomarkers that distinguish DILI from acute liver injury related to alternative etiology. Biomarkers with the potential to identify serious adverse outcomes from acute DILI should be validated in independent prospective cohorts with a substantial number of cases.es_ES
dc.description.sponsorshipThis paper was funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283 (www.imi.europa.eu). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Translational Safety Biomarker Pipeline (TransBioLine): Enabling develop- ment and implementation of novel safety biomarkers in clinical trials and diagnosis of disease’ — ‘TransBioLine’ (‘action’). Grant Number: 821283.es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectHígado -- Enfermedadeses_ES
dc.subjectMedicamentoses_ES
dc.subject.otherDILIes_ES
dc.subject.otherLesión hepática inducida por fármacoses_ES
dc.subject.otherHepatotoxicidades_ES
dc.titleBiomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic reviewes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doi10.1080/17425255.2021.1999410
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem